Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
ORIC Pharmaceuticals, Inc is a biotechnology business based in the US. ORIC Pharmaceuticals shares (ORIC) are listed on the NASDAQ and all prices are listed in US Dollars. ORIC Pharmaceuticals employs 60 staff and has a market cap (total outstanding shares value) of USD$1.3 billion.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Mobile users
Latest market close | USD$34.61 |
---|---|
52-week range | USD$18.6 - USD$40.67 |
50-day moving average | USD$24.6749 |
200-day moving average | USD$26.2176 |
Wall St. target price | USD$43.57 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | N/A |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $34.61 from 2020-12-09
1 week (2021-01-08) | 10.72% |
---|---|
1 month (2020-12-17) | -5.44% |
3 months (2020-10-15) | 48.22% |
6 months (2020-07-15) | 44.81% |
1 year (2020-01-15) | N/A |
---|---|
2 years (2019-01-15) | N/A |
3 years (2018-01-15) | N/A |
5 years (2016-01-15) | N/A |
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -25.36% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | N/A |
Market capitalisation | USD$1.3 billion |
TTM: trailing 12 months
There are currently 2.4 million ORIC Pharmaceuticals shares held short by investors – that's known as ORIC Pharmaceuticals's "short interest". This figure is 5.3% down from 2.5 million last month.
There are a few different ways that this level of interest in shorting ORIC Pharmaceuticals shares can be evaluated.
ORIC Pharmaceuticals's "short interest ratio" (SIR) is the quantity of ORIC Pharmaceuticals shares currently shorted divided by the average quantity of ORIC Pharmaceuticals shares traded daily (recently around 221723.16960148). ORIC Pharmaceuticals's SIR currently stands at 10.79. In other words for every 100,000 ORIC Pharmaceuticals shares traded daily on the market, roughly 10790 shares are currently held short.
However ORIC Pharmaceuticals's short interest can also be evaluated against the total number of ORIC Pharmaceuticals shares, or, against the total number of tradable ORIC Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ORIC Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 ORIC Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.1253% of the tradable shares (for every 100,000 tradable ORIC Pharmaceuticals shares, roughly 125 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ORIC Pharmaceuticals.
Find out more about how you can short ORIC Pharmaceuticals stock.
We're not expecting ORIC Pharmaceuticals to pay a dividend over the next 12 months.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.